Blueprint Medicines Corp. (BPMC)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Blueprint Medicines Corporation (BPMC) Q2 2024 Earnings Call Transcript
Blueprint Medicines Corporation (NASDAQ:BPMC ) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Jenna Cohen - Vice President-Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Christy Rossi - Chief Operating Officer Mike Landsittel - Chief Financial Officer Fouad Namouni - President-Research & Development Conference Call Participants Salveen Richter - Goldman Sachs Brad Canino - Stifel Marc Frahm - TD Cowen Michael Schmidt - Guggenheim Reni Benjamin - Citizens JMP Laura Prendergast - Raymond James Ami Fadia - Needham Matt Biegler - Oppenheimer Andy Berens - Leerink Sudan Loganathan - Stephens Operator Hello, everyone. At this time I would like to welcome everyone to the Blueprint Medicines' Second Quarter 2024 Financial Results Conference Call.
Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates
Blueprint Medicines (BPMC) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $1.28. This compares to loss of $2.19 per share a year ago.
Blueprint Medicines Corporation Investors Are Informed By The Schall Law Firm Of Current Investigations Into Potential Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Blueprint Medicines Corporation Investors Are Informed By The Schall Law Firm Of Current Investigations Into Potential Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / July 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Blueprint Medicines Corporation Investors Are Notified By The Schall Law Firm Of Ongoing Investigations Into Possible Securities Law Breaches
LOS ANGELES, CA / ACCESSWIRE / July 26, 202 4/ The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Blueprint Medicines Corporation Investors Are Notified By The Schall Law Firm Of Ongoing Investigations Into Possible Securities Law Breaches
LOS ANGELES, CA / ACCESSWIRE / July 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?
Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Blueprint Medicines Corporation Investors Are Notified By The Schall Law Firm Of Ongoing Investigations Into Possible Securities Law Breaches
LOS ANGELES, CA / ACCESSWIRE / July 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Blueprint Medicines Corporation Investors Are Notified By The Schall Law Firm Of Ongoing Investigations Into Possible Securities Law Breaches
LOS ANGELES, CA / ACCESSWIRE / July 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Blueprint Medicines Corporation Investors Are Notified By The Schall Law Firm Of Ongoing Investigations Into Possible Securities Law Breaches
LOS ANGELES,CA / ACCESSWIRE / July 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Blueprint Medicines Corporation Investors Are Notified By The Schall Law Firm Of Ongoing Investigations Into Possible Securities Law Breaches
LOS ANGELES, CA / ACCESSWIRE / July 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Blueprint Medicines Corporation Investors Are Informed By The Schall Law Firm Of Ongoing Investigations Into Possible Securities Law Breaches
LOS ANGELES, CA / ACCESSWIRE / July 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
